Investigational New Drug (IND) application procedure is a key regulatory pathway that allows new pharmaceuticals to move from laboratory research into human clinical trials. This introduction covers essential concepts B.Pharm students must master: IND submission components, CMC (chemistry, manufacturing and controls), nonclinical toxicology, GLP and GMP requirements, safety reporting, sponsor and investigator responsibilities, protocol amendments, and FDA review timelines. Understanding these elements helps you design, evaluate, and manage early-phase clinical research ethically and compliantly. The following questions reinforce core principles, regulatory expectations, and practical steps in preparing and managing an IND. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is an Investigational New Drug (IND) application?
- A marketing application to obtain drug approval for sale
- A regulatory submission to begin human clinical trials
- A manufacturing license for commercial production
- A patent application for a new chemical entity
Correct Answer: A regulatory submission to begin human clinical trials
Q2. What is the primary purpose of an IND?
- To obtain pricing approval from payers
- To allow human exposure while ensuring subject safety
- To request orphan drug designation
- To register a drug for over-the-counter sale
Correct Answer: To allow human exposure while ensuring subject safety
Q3. Which nonclinical data are essential before filing an IND?
- Phase III clinical results
- Nonclinical pharmacology and toxicology studies
- Post-marketing surveillance reports
- Healthcare economic models
Correct Answer: Nonclinical pharmacology and toxicology studies
Q4. What does CMC stand for in an IND application?
- Clinical Monitoring Committee
- Chemistry, Manufacturing, and Controls
- Clinical Medical Certification
- Compliance and Monitoring Checklist
Correct Answer: Chemistry, Manufacturing, and Controls
Q5. Which form is commonly associated with IND sponsor commitments in the US?
- Form FDA 1571
- Form FDA 3500
- Form FDA 483
- Form FDA 3458
Correct Answer: Form FDA 1571
Q6. Which of the following is a recognized type of IND?
- Marketing IND
- Investigator IND
- Generic IND
- Pharmacoeconomic IND
Correct Answer: Investigator IND
Q7. What is the standard FDA review period after initial IND submission before clinical work may proceed if there is no hold?
- 7 days
- 15 days
- 30 days
- 90 days
Correct Answer: 30 days
Q8. What does a “clinical hold” mean in the IND context?
- Immediate approval to start trials
- Delay or suspension of clinical investigation
- A financial freeze on the sponsor
- A requirement to publish trial results
Correct Answer: Delay or suspension of clinical investigation
Q9. Which responsibility is primarily that of the sponsor under IND regulations?
- Securing IRB approval for each site
- Ensuring overall safety monitoring and IND compliance
- Prescribing study medication to subjects
- Performing routine laboratory tests at local clinics
Correct Answer: Ensuring overall safety monitoring and IND compliance
Q10. What information is typically included in the Investigator’s Brochure?
- Marketing strategies and pricing
- Preclinical and clinical data relevant to investigators
- Manufacturing batch release certificates only
- Investigator personal financial records
Correct Answer: Preclinical and clinical data relevant to investigators
Q11. What does GLP refer to in nonclinical studies supporting an IND?
- Good Laboratory Practice
- General Licensing Protocol
- Good Logistics Provision
- Global Legal Procedure
Correct Answer: Good Laboratory Practice
Q12. Which standard addresses production quality for materials used in clinical trials?
- GCP (Good Clinical Practice)
- GMP (Good Manufacturing Practice)
- GDP (Good Distribution Practice)
- GSP (Good Study Practice)
Correct Answer: GMP (Good Manufacturing Practice)
Q13. Where in an IND would you find details of drug formulation and stability?
- Investigator’s qualifications
- Chemistry, Manufacturing, and Controls (CMC)
- Clinical protocol synopsis
- Adverse event line listings
Correct Answer: Chemistry, Manufacturing, and Controls (CMC)
Q14. Serious, unexpected, suspected adverse reactions that are fatal or life-threatening must typically be reported to the FDA within:
- 1 year
- 30 days
- 7 calendar days
- 90 days
Correct Answer: 7 calendar days
Q15. A protocol amendment is required when the sponsor:
- Changes a study’s inclusion/exclusion criteria or dose regimen
- Sends investigators routine newsletters
- Makes no changes but documents annual progress
- Replaces study stationery
Correct Answer: Changes a study’s inclusion/exclusion criteria or dose regimen
Q16. What is an emergency use IND (commonly single-patient IND)?
- A marketing permit for emergency drugs
- Authorization to treat a single patient when no approved options exist and no time for full IND submission
- A pediatric exclusivity application
- A batch release certificate for clinical supply
Correct Answer: Authorization to treat a single patient when no approved options exist and no time for full IND submission
Q17. In an investigator IND, who holds IND responsibilities?
- The contract research organization only
- The clinical laboratory performing tests
- The investigator who initiates and conducts the study
- The hospital pharmacy alone
Correct Answer: The investigator who initiates and conducts the study
Q18. What is the main objective of Phase I clinical trials?
- Confirming long-term efficacy in large populations
- Assessing safety, tolerability, and pharmacokinetics in humans
- Comparing cost-effectiveness to marketed drugs
- Obtaining marketing approval
Correct Answer: Assessing safety, tolerability, and pharmacokinetics in humans
Q19. Phase II trials mainly aim to:
- Evaluate preliminary efficacy and dose selection
- Monitor long-term safety in thousands of patients
- Apply for patent protection
- Perform post-marketing surveillance
Correct Answer: Evaluate preliminary efficacy and dose selection
Q20. Phase III clinical trials are designed to:
- Explore drug metabolism in animals
- Confirm efficacy and further characterize safety in large populations
- Produce manufacturing validation batches only
- Test surgical procedures
Correct Answer: Confirm efficacy and further characterize safety in large populations
Q21. What is FDA Form 1572?
- An application for orphan drug status
- Statement of Investigator outlining commitments and qualifications
- A labeling approval form
- A chemical batch release form
Correct Answer: Statement of Investigator outlining commitments and qualifications
Q22. When is an IND number typically assigned?
- Only after final marketing approval
- Upon the FDA’s acceptance/administrative processing of the IND submission
- When the first patient completes the trial
- At the time of patent filing
Correct Answer: Upon the FDA’s acceptance/administrative processing of the IND submission
Q23. Who is the sponsor-investigator?
- An investigator who also takes on sponsor responsibilities for a study
- A pharmaceutical sales representative
- The institutional review board chairperson
- The contract manufacturing organization
Correct Answer: An investigator who also takes on sponsor responsibilities for a study
Q24. What is the role of the Institutional Review Board (IRB) in IND studies?
- Approving scientific manufacturing methods
- Reviewing and approving study protocol and informed consent to protect subjects
- Granting marketing exclusivity
- Distributing study medication to pharmacies
Correct Answer: Reviewing and approving study protocol and informed consent to protect subjects
Q25. Typical nonclinical toxicology studies supporting IND include:
- Repeat-dose toxicity and genotoxicity studies
- Only marketing surveys
- Human epidemiology studies
- Cost-benefit analyses
Correct Answer: Repeat-dose toxicity and genotoxicity studies
Q26. Why is stability data important in the CMC section of an IND?
- To determine the drug’s pharmacodynamics in humans
- To justify the proposed shelf life and storage conditions for clinical supplies
- To evaluate investigator qualifications
- To file for tax exemptions
Correct Answer: To justify the proposed shelf life and storage conditions for clinical supplies
Q27. What action can the FDA take if safety concerns arise after IND submission?
- Grant an immediate marketing license
- Place a clinical hold on the investigation
- Transfer the IND to another sponsor automatically
- Increase drug pricing limits
Correct Answer: Place a clinical hold on the investigation
Q28. When may clinical dosing proceed without waiting the full 30-day review period?
- Never; dosing must always wait 30 days
- Only if FDA grants a waiver in writing or there is no clinical hold
- As soon as the sponsor decides
- When the study is in Phase III only
Correct Answer: Only if FDA grants a waiver in writing or there is no clinical hold
Q29. Who is primarily responsible for protecting the rights, safety, and welfare of subjects at a clinical site?
- The drug manufacturer’s sales team
- The institutional review board alone
- The clinical investigator conducting the trial
- The marketing department of the sponsor
Correct Answer: The clinical investigator conducting the trial
Q30. After successful IND-supported clinical trials, the sponsor typically submits which application for marketing approval?
- A Phase IV notification
- A New Drug Application (NDA) or Biologics License Application (BLA)
- An Investigator IND form
- A Good Laboratory Practice certificate
Correct Answer: A New Drug Application (NDA) or Biologics License Application (BLA)
